Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nasal Glucagon Approved for Severe Hypoglycemia

Nasal Glucagon Approved for Severe Hypoglycemia News & Analysis News From the Food and Drug Administration Nasal Glucagon Approved for Severe and tendon sheaths to overgrow and dam- with complicated urinary tract infection Hypoglycemia age surrounding tissue. The tumor can (UTI) and complicated intra-abdominal The first glucagon therapy for treating se- occur in large or small joints, depending on infection (IAI) who have few or no other vere hypoglycemia without an injection the subtype. treatment options. has received FDA approval. Marketed as Marketed as Recarbrio, the drug com- Baqsimi, the intranasal powder is indicated bines imipenem-cilastatin, a previously totreatseverehypoglycemiainpatientswith FDA-approved antibiotic, and relebactam, diabetes who are aged 4 years or older. a new β-lactamase inhibitor, in injection Baqsimi is packaged in a tube with form. (Cilastatin limits the renal metabo- a plunger that patients push to stream the lism of imipenem; it has no antibacterial powder into a nostril. Janet Woodcock, MD, activity.) The agency noted that health director of the FDA’s Center for Drug Evalu- professionals should dispense the drug ation and Research, noted that until now, judiciously to prevent drug-resistant bac- people having a severe hypoglycemic epi- teria from developing. sode needed an intramuscular glucagon in- “It is important that the use of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Nasal Glucagon Approved for Severe Hypoglycemia

Voelker, Rebecca
JAMA , Volume 322 (9) – Sep 3, 2019
Download PDF
1 page

Nasal Glucagon Approved for Severe Hypoglycemia

Abstract

News & Analysis News From the Food and Drug Administration Nasal Glucagon Approved for Severe and tendon sheaths to overgrow and dam- with complicated urinary tract infection Hypoglycemia age surrounding tissue. The tumor can (UTI) and complicated intra-abdominal The first glucagon therapy for treating se- occur in large or small joints, depending on infection (IAI) who have few or no other vere hypoglycemia without an injection the subtype. treatment options. has received FDA approval....
Loading next page...
 
/lp/american-medical-association/nasal-glucagon-approved-for-severe-hypoglycemia-F8jEjOOxgO

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.12938
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration Nasal Glucagon Approved for Severe and tendon sheaths to overgrow and dam- with complicated urinary tract infection Hypoglycemia age surrounding tissue. The tumor can (UTI) and complicated intra-abdominal The first glucagon therapy for treating se- occur in large or small joints, depending on infection (IAI) who have few or no other vere hypoglycemia without an injection the subtype. treatment options. has received FDA approval. Marketed as Marketed as Recarbrio, the drug com- Baqsimi, the intranasal powder is indicated bines imipenem-cilastatin, a previously totreatseverehypoglycemiainpatientswith FDA-approved antibiotic, and relebactam, diabetes who are aged 4 years or older. a new β-lactamase inhibitor, in injection Baqsimi is packaged in a tube with form. (Cilastatin limits the renal metabo- a plunger that patients push to stream the lism of imipenem; it has no antibacterial powder into a nostril. Janet Woodcock, MD, activity.) The agency noted that health director of the FDA’s Center for Drug Evalu- professionals should dispense the drug ation and Research, noted that until now, judiciously to prevent drug-resistant bac- people having a severe hypoglycemic epi- teria from developing. sode needed an intramuscular glucagon in- “It is important that the use of

Journal

JAMA – American Medical Association

Published: Sep 3, 2019

There are no references for this article.